跳至主要内容
临床试验/NCT03662620
NCT03662620已完成1 期

A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers

Yuhan Corporation1 个研究点 分布在 1 个国家目标入组 67 人开始时间: 2018年10月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
67
试验地点
1
主要终点
Cmax of Telmisartan/amlodipine/chlorthalidone

研究概览

简要总结

This is a phase 1, randomized, open label, single-dose, replicate crossover clinical trial to compare the safety and pharmacokinetics of YH22162 in healthy male volunteers.

Hypothesis: Study drug and comparator drug are showing equal pharmacokinetics.

详细描述

In ARM1, 32 subjects will be assigned and the subjects will be administered "comparator drug" at Day1/Day43 and "study drug" at Day22/64.

In ARM2, 32 subjects will be assigned and the subjects will be administered "study drug" at Day1/Day43 and "comparator drug" at Day22/64.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male with body mass index(BMI) between 18.5 and 30 kg/m2
  • Who has not suffered from clinically significant disease
  • Provision of signed written informed consent

排除标准

  • History of and clinically significant disease
  • Administration of other investigational products within 3 months prior to the first dosing
  • Volunteers considered not eligible for the clinical trial by the investigator due to reasons including laboratory test results, ECGs, or vital signs

研究组 & 干预措施

ARM1

Experimental

In ARM1, 32 subjects will be assigned and the subjects will be administered "comparator drug" at Day1/Day43 and "study drug" at Day22/64.

干预措施: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg (Drug)

ARM2

Experimental

In ARM2, 32 subjects will be assigned and the subjects will be administered "study drug" at Day1/Day43 and "comparator drug" at Day22/64.

干预措施: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg (Drug)

结局指标

主要结局

Cmax of Telmisartan/amlodipine/chlorthalidone

时间窗: 0-168 hrs

Cmax

AUClast of Telmisartan/amlodipine/chlorthalidone

时间窗: 0-168 hrs

AUClast

次要结局

  • t1/2 of Telmisartan/amlodipine/chlorthalidone(0-168 hrs)
  • AUCinf of Telmisartan/amlodipine/chlorthalidone(0-168 hrs)
  • Tmax of Telmisartan/amlodipine/chlorthalidone(0-168 hrs)

研究者

发起方
Yuhan Corporation
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验